ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Biosero and Virscidian Announce Collaboration for Medicinal Chemistry Applications in Drug Discovery

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, and Virscidian, developer of solutions to automate LC/MS (liquid chromatography and mass spectrometry) decision-driven workflows, today announced a collaboration and co-marketing agreement through which the companies will support fully automated analytical workflows for medicinal chemistry as well as other scientific applications, including accelerated screening for drug metabolism and pharmacokinetics (DMPK).

Virscidian developed the Analytical Studio platform (including Analytical Studio Professional™ and Analytical Studio Express™ software) to accelerate drug discovery. The software automates analysis of mass spectrometric and chromatographic data to provide actionable intelligence, such as the identity and quantification of compounds of interest, optimal analytical and preparative LC/MS conditions, reaction monitoring, and much more. It also provides users with ranked lists of results to streamline decisions about what steps to take next, and which compounds to move forward in the discovery and development pipeline. Biosero provides Green Button Go® laboratory automation software to schedule, coordinate, and manage the physical flow of materials, the control of instruments, and the digital flow of information on workstations or throughout entire laboratory facilities.

By working together, Biosero and Virscidian are enabling their customers to easily transfer data between these software platforms so that full medicinal chemistry and analytical workflows can be automated. Software-powered conversion of analytical data into actionable decisions can be used to control which compounds are moved to the next stage, which instruments are tasked to run them, and under what conditions. This approach means that more compounds can be tested and moved into follow-up analysis, reducing or removing the need for human intervention. Biosero and Virscidian are currently working together on more than 10 projects around the world where customers are already realizing the benefits of this collaboration.

“At Virscidian, we aim to provide actionable intelligence that streamlines compound synthesis, purification, and screening, enabling scientists to spend their time on the highest-value tasks without compromising laboratory productivity,” said Joseph Simpkins, CEO at Virscidian. “Thanks to our collaboration with the Biosero team, our customers now have access to a validated Green Button Go plugin that seamlessly integrates our analysis-based intelligence with the ability to physically control the scientific process and instrumentation accordingly.”

Ryan Bernhardt, Chief Commercial Officer at Biosero, commented: “Based on our close work with customers in the drug discovery and development space, we know there is high demand in biopharma companies to automate medicinal chemistry applications and accelerate compound screening in areas such as DMPK. We are pleased to join forces with Virscidian as we make this connection between our software platforms to help customers streamline drug discovery from synthesis through to registered material and screening results.”

About Virscidian

Virscidian is a privately owned company composed of experts in identifying, designing, and implementing decision-driven solutions to enhance productivity in biopharmaceutical and agricultural value chains. Virscidian’s scientific analytical desktop and enterprise software helps customers, independently of the vendor instrumentation, automate reaction screening, end-to-end purification, affinity selection by mass spectrometry, compound quality control, drug metabolism and pharmacokinetics and other high-throughput analytical techniques. Their solutions transform raw data into actionable intelligence that improves productivity and the quality of results, enabling chemists and project teams to make complex decisions from large amounts of data with confidence in the results. Their solutions are easily integrated and provide the critical decisions to drive some of the most sophisticated automation platforms in the world.

About Biosero, Inc.

Biosero, a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Biosero’s Green Button Go® Scheduler software and integration services match laboratory automation to science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Additionally, Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. Biosero is passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs. For more information, please visit www.biosero.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.